Company intelligence / Profile preview

Wasatch BioLabs

Pleasant Grove, Utah, USA

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Wasatch BioLabs has launched multiple proprietary methylation sequencing products including cell-free whole genome methylation sequencing assays and the Direct Whole Methylome Sequencing (dWMS) platform, enabling single-molecule, comprehensive methylation analysis with clinical and research applicability. The company has key collaborations for technology development and clinical adoption, but there are no drug development pipelines or clinical trials for therapeutics; its focus is on advanced diagnostics and sequencing services.[2][3][4][6][7]

Therapeutic areas: OncologyOther
Modalities: DNA sequencingRNA sequencingEpigenomic assayGenomic assay
Industry: Molecular Diagnostics

Partnerships

Oxford Nanopore Technologies

Beyond the preview

Go deeper on Wasatch BioLabs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wasatch BioLabs.

Explore the full profile